JAZZ 在北美地区（美国和加拿大）引入了这款药，2021年销售接近2.5亿美金， 算是一个重磅单品了。JAZZ 和 Pharma Mar目前还在推进这款药的一些临床试验，包括一个治疗实体瘤的二期临床， Lurbinectedin + PD-L1 一线治疗SCLC三期临床， 以及Lurbinectedin二线治疗SCLC的确认性临床。尽管有些不确定性，这款药还是值得期待的。特别是绿叶基本上就是在“躺赢”，不用冒太大的风险，只要跟随就好了。以下是JAZZ 2021年报关于Lurbinectedin的一些节选：
Zepzelca (lurbinectedin):
Zepzelca net product sales were $246.8 million in 2021, the first full calendar year on the market following launch in July 2020, and increased 21% to $64.8 million in 4Q21 compared to 4Q20.The Company is pleased to have established Zepzelca as the treatment of choice in the second-line SCLC setting after only eighteen months on the market.Zepzelca development program updates:The Company has initiated the Phase 2 basket trial evaluating Zepzelca as monotherapy in select relapsed/refractory solid tumors.Jazz and collaborator F. Hoffmann-La Roche Ltd (Roche) have initiated a Phase 3 trial to evaluate first-line use of Zepzelca in combination with Tecentriq® (atezolizumab), compared to Tecentriq alone, as maintenance therapy, in patients with extensive-stage SCLC after induction chemotherapy. The first patient was enrolled in November 2021.The Company's partner, PharmaMar, initiated a confirmatory trial, LAGOON, in second-line SCLC in December 2021. If positive, this trial would confirm the benefit of Zepzelca in the treatment of SCLC when patients progress following first-line treatment with a platinum-based regimen. $绿叶制药(02186)$